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Purpose: The intent of this study was to assess the safety and effectiveness of the Zenith AAA Endovascular Graft
compared with conventional aneurysm repair.
Material and methods: The study was conducted in a prospective, multicenter, nonrandomized, concurrent control
manner. Physiologically similar patients with infrarenal abdominal aortic aneurysms (AAAs) underwent either open
surgery or repair with the Zenith AAA Endovascular Graft. Separate analyses of physiologically challenged patients were
performed. Follow-up was conducted at hospital discharge and at 1, 6, and 12 months (endovascular repair group) or 1
and 12 months (open surgical repair group). Evaluation included computed tomography, abdominal radiography,
laboratory tests, and physical examination. Mortality (AAA-related and overall), morbidity, in-hospital recovery, renal
function, and secondary interventions were assessed. Patients in the endovascular repair group were evaluated for change
in aneurysm size, endoleak, graft migration, conversion, rupture, and device integrity. Statistical analyses were performed
with the Kaplan-Meier method, Blackwelder test, propensity score assessment, two-sample t test, Yates-corrected Pearson
2 test, and Fisher exact test.
Results: Conventional open surgery was used in 80 patients, and 200 patients underwent repair with the Zenith AAA
Endovascular Graft. Technical success was accomplished in 98.8% of patients in the open repair group and 99.5% in the
endovascular repair group. Patients in the endovascular repair group had fewer significant adverse events within 30 days
(80% vs 57%; P < .001). All-cause mortality was similar (endovascular, 3.5%; open surgery, 3.8%). Aneurysm-related
mortality was higher with conventional surgery at 12 months (3.8% vs 0.5%; P  .04). In-hospital recovery and
procedural measures were better for endovascular repair in all categories (P < .001). The incidence of endoleak was 17%
at 30 days, 7.4% at 12 months, and 5.4% at 24 months. Aneurysm shrinkage (>5 mm) was noted in more than two thirds
of patients at 12 months and three fourths of patients at 24 months. Renal dysfunction rate did not differ between
groups. Migration (>5 mm) was detected in four (2%) patients through 12 months; none was greater than 10 mm or
associated with adverse events through 24 months. Three conversions were performed within 12 months, one because of
aneurysm rupture. Secondary procedures were more common in the endovascular group (11% vs 2.5%; P .03). In total,
351 patients had endografts implanted, and 6 patients were noted to have barb separations through 12-month follow-up.
No stent fractures were noted.
Conclusions: The Zenith AAA Endovascular Graft is safe and effective for treatment of infrarenal AAAs. The high
likelihood of decrease in aneurysm size provides evidence that treatment of aneurysms with this device reverses the natural
history of aneurysmal disease. The importance of long-term follow-up is underscored by the small but defined incidence
of barb separation and the potential for unforeseen failure modes. (J Vasc Surg 2004;39:1209-18.)In the decade since introduction of endovascular aneu-
rysm repair1 the field has advanced steadily via improve-
ments in system design. Late-generation devices benefit
from features such as bifurcated configurations, modular-
ity, full stent support, secure fixation systems, and struc-
tures capable of accommodating anatomic changes. The
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Long-term results from experience in Australia, Europe,
and the United States have been reported.6 However, it
must be understood that most results pertaining to the
Zenith endovascular graft system before the present publi-
cation have included combined experiences with predicate
designs and variable inclusion criteria. This article summa-
rizes a US multicenter Zenith clinical trial, which was
initiated in January 2000. The study design used the same
nonrandomized, concurrently controlled design used in
US trials of other devices.7,8
Fig 1. Zenith AAA Endovascular Graft main body and iliac legs.MATERIAL AND METHODS
Device description. The Zenith AAA Endovascular
Graft is a three-piece modular system, including a bifur-
cated aortic main body and two iliac legs, with available
ancillary components (Fig 1). All devices incorporate self-
expanding stainless steel Z-stents attached to traditional
polyester graft material with currently marketed suture
material. The size of each device is selected to match
individual patient anatomy (Appendix 1, online only).
Proximal graft diameter ranges from 22 to 32 mm, and iliac
diameter from 8 to 24 mm. The devices are supplied sterile
and preloaded onto the H&L-B One-Shot introduction
system. An uncovered stent with staggered barbs is located
at the top of the main body for suprarenal fixation. Ancillary
components, such as main body extenders, iliac leg extend-
ers, converters, and occluders, are used to provide supple-
mental proximal or distal coverage or to convert a bifur-
cated graft to an aortomonoiliac graft if deemed necessary.
Study design. This multicenter clinical trial had a
prospective, nonrandomized, concurrently controlled de-
sign, and data were analyzed with an intention-to-treat
method. The objective of the study was to determine the
safety and effectiveness of endovascular aneurysm repair
with the Zenith AAA Endovascular Graft compared with
conventional open surgical repair in patients with similar
pathophysiologic features. Four groups of patients were
established to properly identify the distinct populations
(Table I). One study group, who received endovascular
therapy yet were deemed physiologically capable of with-
standing open surgical repair (standard risk endovascular
group [ZSR]) was compared with a group that underwent
conventional surgical repair (standard surgical risk group
[SSR]). These two study groups concurrently enrolled
patients with similar pathophysiologic risk, but the patients
may have differed anatomically as a result of anatomic
limitations of the endograft (these were accounted for with
a propensity analysis). A separate subset of patients with
more significant comorbid conditions, believed to be at
high risk for complications from open repair, were enrolled
in a high-risk group (high-risk endovascular group
[ZHR]). A fourth group consisted of patients who received
treatment at centers that were achieving familiarity with the
device before accrual of pivotal patients (roll-in endovascu-
lar group [ZRI]). These patients met the anatomic and
medical inclusion criteria for either the ZSR or ZHR
groups.
Follow-up included clinical examination; laboratory
studies, including serum creatinine concentration (SCr)
and blood urea nitrogen (BUN); and imaging studies at
discharge, and at 1, 6, 12, and 24 months in the endovas-
cular group or at 1 and 12 months in surgical group.
Imaging included three-phase, contrast material–en-
hanced, high-resolution computed tomography (CT) in
the open surgery and endovascular groups, and four-view
abdominal radiography in the endovascular group. The
study hypotheses were based on 1-month and 12-month
end points. An independent core image analysis laboratory
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Clinic Foundation) analyzed all imaging studies, and is the
source of the imaging data reported here. A clinical events
committee (Harvard Clinical Research Institute) reviewed
and adjudicated adverse events, and categorized them as
related (procedure, technique, device) or unrelated to ab-
dominal aortic aneurysm (AAA) repair. An independent
data safety monitoring board was responsible for interim
analyses and addressed all study safety issues. Fifteen US
centers participated in this clinical study (Table II, online
only). The respective institutional review boards approved
the clinical protocol and patient consent forms. All patients
provided voluntary informed consent.
Study hypotheses. The pivotal study hypotheses in-
volved a comparison of outcomes for the ZSR and SSR
groups. The primary hypothesis was that treatment of
AAAs with the Zenith AAA Endovascular Graft is associ-
ated with less morbidity than is open surgical repair. Mor-
bidity was evaluated at 30 days post-procedure as freedom
from any significant morbidity, and with a conglomerate
end point of 31 measures representing seven organ-based
groups, including cardiac, pulmonary, renal, vascular, gas-
trointestinal, wound, and neurologic complications (Com-
bined Morbidity Index Scoring System; see Appendix 2,
online only). This scoring system was not weighted or
validated, but included common complications cited by
several articles defining morbid events from both open9-12
and endovascular3,13,14 aneurysm repair and included in-
put from the US Food and Drug Administration (FDA).
Three success measures involved both clinical and im-
aging assessments and were defined as follows:
• Technical success: prosthesis delivery, deployment, and
delivery device removal, or successful implantation of a
surgical graft resulting in a patent prosthesis.
• Procedural success: technical success without any major
complications through 30 days, and absence of type I or
type III endoleak at the 30-day examination.
• Treatment success: technical success without any major
complications through 12 months, absence of type I or
type III endoleak at the 12-month examination, and
absence of aneurysm enlargement (5 mm) at 12
months.
Major complications precluding success included
death, rupture, conversion, Q-wave myocardial infarction,
congestive heart failure, cardiac ischemia requiring inter-
vention, renal failure requiring dialysis, bowel obstruction,
bowel ischemia, bowel fistula, stroke, paralysis, and aneu-
rysm leak or rupture. In-hospital recovery was measured
with respect to length of stay, days in the intensive care unit,
days to ambulation, and days to resumption of fluid intake,
regular diet, and normal gastrointestinal function. Addi-
tional procedural measures included procedural time, esti-
mated blood loss, and use of blood bank products. Second-
ary hypotheses included equivalent survival at 30 days and
12 months (aneurysm- related and all-cause mortality de-
fined by the reporting standards document15), equivalenttreatment success at 12 months, and improved in-hospital
recovery.
Endoleak was classified as types I through IV according
to standard definitions,16,17 and further defined in compli-
ance with reporting standards.15 Device position, with
respect to native arterial vasculature, was assessed. Proximal
device migration was defined as movement of the proximal
portion of the prosthesis more than 5 mm with respect to
the origin of the lowest renal artery, as noted on CT scans.
Component separation was qualitatively assessed from flat-
plate abdominal radiographs. Change in aneurysm size was
evaluated with area, and major and minor axis measure-
ments, obtained from the axial image that demonstrated
the largest major diameter. A change in major diameter
Table I. Physiologic risk criteria differentiating patients at
high or low risk for conventional aneurysm repair
Physiologic exclusion criteria for
standard medical risk groups
(ZSR, SSR)
Anatomic exclusion criteria for
endovascular repair (ZSR,
ZHR, ZRI)
Age 80 years Proximal neck 15 mm long
Baseline SCr 2.0 mg/dL
Receiving home oxygen therapy
FEV1 1 L
Ejection fraction 25%
Disabling COPD
New York Heart classification 3
or 4
Hostile abdomen
Dialysis
Myocardial infarction within last
6 mo
Medically intractable
hypertension
Previous stroke with residual
deficit
Cultural objection to receipt of
blood or blood products
Previous renal bypass surgery
Inflammatory aneurysm
Age younger than 18 years
Life expectancy 2 years
Pregnancy
Unwilling to comply with
follow-up schedule
Inability or refusal to give
informed consent
Allergy to stainless steel or
polyester
Anaphylactic reaction to
contrast material
Leaking, ruptured, or
symptomatic aneurysm
Uncorrectable coagulopathy
Proximal neck (measured
outer wall to outer wall on a
sectional image [CT]) 28
mm or 18 mm in diameter
Proximal neck angulated 60
degrees relative to long axis
of aneurysm
Immediate suprarenal neck
angulated 45 degrees
relative to immediate
infrarenal neck
Proximal neck inverted funnel
shaped
Proximal neck with
circumferential thrombus or
atheroma
Iliac artery diameter
(measured inner wall to
inner wall on a sectional
image [CT]) 7.5 mm
Iliac artery diameter
(measured outer wall to
outer wall on a sectional
image [CT]) 20 mm at
distal fixation site
Iliac artery distal fixation site
10 mm long
Indispensable inferior
mesenteric artery
Inability to maintain at least
one patent hypogastric artery
Unsuitable arterial anatomy
Specific anatomic exclusion
criteria for standard medical
risk groups (SSR, ZSR)
Significant occlusive disease,
tortuosity, or calcification
Renal artery stenosis 80%
ZSR, Zenith standard risk group; SSR, surgical standard risk group; ZHR,
Zenith high-risk group; ZRI, Zenith roll-in group; SCr, serum creatinine
concentration; FEV 1, forced expiratory volume in 1 second; COPD, chronic
obstructive pulmonary disease; CT, computed tomography.
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tegrity was assessed with CT, abdominal flat-plate radiog-
raphy, and explant analysis when available. The need for
secondary intervention to treat AAA-related observations
was evaluated. The effect of the suprarenal stent on the
function of the kidneys was evaluated with functional and
anatomic renal assessments. Any patient with an increase in
serum creatinine concentration (SCr) greater than 30%
from baseline, and all patients with SCr greater than 2.0
mg/dL were considered to have renal insufficiency and
were carefully assessed. The anatomic status of the renal
artery and renal parenchyma was established with evalua-
tion of CT scans at follow-up visits and supplemented with
any available duplex ultrasound scans or angiograms. The
specific effect of neck length and clamp location was eval-
uated in the surgical group by comparing those patients
with suprarenal clamps with those with infrarenal clamps.
Furthermore, patients in the ZSR group were compared
with the full cohort of surgical control subjects and with the
subset with only infrarenal clamps.
Repair techniques. All open surgical repairs were per-
formed with the patient under general anesthesia, and were
accomplished via a transperitoneal or retroperitoneal ap-
proach. Placement of an infrarenal, suprarenal, or suprace-
liac clamp depended solely on surgeon preference. In all
patients the proximal anastomosis was sewn to the infrare-
nal aorta with a tube or bifurcated graft. The Zenith AAA
Endovascular Graft was used for all endovascular implanta-
tions. Deployment technique details have been de-
scribed,5,6 and are available in Appendix 1, online only.
Statistical analysis. Analyses were performed with
Systat versions 10 and 10.2 (SPSS). Conclusions were
drawn for both continuous and dichotomous measures,
with independent two-sample t tests, Yates-corrected Pear-
son 2 test, or Fisher exact test, as appropriate. P .05 was
considered significant. Equivalence (non-inferiority) was
tested according to the method of Blackwelder,18 with  
0.075. A propensity score was calculated on the basis of
potential differences between ZSR and SSR groups in
demographic, pathophysiologic, and anatomic measures.
Multivariate analysis with a quintile propensity score sub-
classification was used to assess the potential effects of
intergroup differences on outcome and to ensure that
inferences drawn from the data were reasonable. Hypoth-
esis testing for clinical utility was performed independently
for each measure. Pivotal group comparisons were between
the ZSR and SSR groups and pertained to specific mea-
sures. Issues such as conversion to open repair, rupture, and
device integrity were analyzed with respect to all endovas-
cular groups (ZSR, ZHR, and ZRI). MED Institute, a
Cook Group company, and STATKING, a private consult-
ing company, conducted the statistical analyses.
Author roles. Three authors (R.K.G., T.A.M.C.,
N.F.) participated in protocol development; all authors
were involved in interpretation and review of the data, and
methods and interpretation of statistical analyses, and were
solely responsible for preparation of the manuscript. The
sponsor granted full access to the data, and the authorschose where to submit the manuscript and approved the
completed document. The sponsors reviewed the manu-
script for technical accuracy and proprietary information.
The principal investigators at the respective sites were re-
sponsible for ensuring proper conduct of the study and data
collection. The co-investigators were involved in patient
enrollment and data accrual.
RESULTS
Enrollment was begun in January 2000, and was com-
pleted in July 2001. Two hundred patients were enrolled in
the ZSR group, 80 in the SSR group, 100 in the ZHR
group, and 52 in the ZRI group.
Patient characteristics. Evaluation of the multitude
of preexisting comorbid conditions or risk factors showed
similar preoperative demographic and pathophysiologic
characteristics in the ZSR and SSR pivotal study groups,
with a few exceptions. The only differences were older age
(P  .03) and greater body weight (P  .002) in the ZSR
group, and a higher incidence of smoking (P  .03),
hypertension (P  .001), and alcohol use (P  .04) in the
SSR group (Table III, online only). Protocol-driven ana-
tomic differences included longer proximal neck length (33
 13.8 vs 20.9  14.4; P  .001), more regular neck
anatomy (90% regular vs 66% regular; P  .001), smaller
aneurysms (56.2 8.8 mm vs 63.8 11.3 mm; P .001),
and lower prevalence of aortoiliac aneurysms (20% vs 42%;
P .001) in the ZSR group compared with the SSR group.
These variables were accounted for by subclass allocation in
the propensity score analysis. In 14 patients in the SRS
group clamps were placed above the renal arteries. Al-
though this patient subset may have had more challenging
anatomy in contrast to other surgical control subjects, there
were no deaths in this group.
Primary hypothesis. Analysis of 30-day morbidity
demonstrated that the ZSR group fared better than the SSR
group with respect to freedom from any morbidity (80% vs
57%; P .001) and mean morbidity score (0.26 0.59 vs
0.92 1.52; P .001). These results remained sound after
adjustment for propensity score subclass (P  .001). Eval-
uation of specific categories within the combined morbidity
index at 30 days demonstrated improved results in the ZSR
group, compared with the SSR group, with respect to
cardiac (3.0 % vs 11%; P .02), pulmonary (1.0% vs 15%; P
 .001), renal (2.5% vs 10%; P .01), and vascular (11% vs
31%; P  .001) morbidities. When compared with the
subset of patients in the SSR group with infrarenal clamps
only, all differences remained significant, with the excep-
tion of renal morbidity (P  .06).
Secondary hypotheses. Mortality was compared at 30
days and at 12 months in the ZSR and SSR groups (Fig 2),
and again at 24 months in the ZSR group. No differences in
30-day mortality (ZSR, 0.5%; SSR, 2.5%) or all-cause mor-
tality (ZSR, 3.5%; SSR, 3.8%) through 12 months were
noted. AAA-related mortality was lower in the ZSR group
(ZSR, 0.5%; SSR, 3.8%; P  .04) through 12 months.
Propensity analysis of all-cause mortality identified no dif-
ferences between the pivotal study groups.
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pivotal study groups (ZSR, 99.5%; SSR, 98.8%; P  .49).
There was only one technical failure each in the ZSR and
SSR groups. In one patient in the ZSR group the delivery
system could not be introduced through a calcified iliofem-
oral vessel, and one patient in the SSR group died of
intraoperative hemorrhage. Procedural success was also
high in each arm (ZSR, 95%; SSR, 88%; P  .06). Propen-
sity score analysis demonstrated no differences between the
two groups (P .19). Treatment success, implying absence
of major adverse events, no type I or III endoleak, and
aneurysm growth, was 89% in the ZSR group and 85% in
the SSR group. With the Blackwelder z statistic, the ZSR
group was non-inferior compared with the SSR group (P
.02). Aneurysm size decreased in more than two thirds of
patients at 12 months and in three fourths of patients at 24
months (Fig 3). The rate of decrease in aneurysm size is
shown in Fig 4, online only. In only three aneurysms was
growth noted after 12 months of observation, in a single
patient with a persistent distal endoleak, and two patients
with subclinical graft infections, both of whom later under-
went conversion to open repair and explantation of the
graft. Two additional patients exhibited aneurysm growth
at 24 months, which was attributed to persistent type II
Fig 2. A, Expanded-axis Kaplan-Meier plot of overall su
(SSR; black line), and through 24 months in the stand
endovascular group (SSR; green line). SSR follow-up
statistical difference between the SSR and ZHR groups (P
through 12 months for SSR group (black line), and thr
(green line). At 12 months there was improved survival
Three deaths in the SSR group were noted through 12 m
deaths occurred in the ZSR group, one attributed to the
and six unrelated to the procedure (prostate cancer, li
patients with preexisting pulmonary fibrosis, and subdurendoleak, treated with coil embolization in both patients.
Clinical utility with respect to procedural measures and
in-hospital recovery was statistically better in the ZSR
group compared with the SSR group (P .001); details are
provided in Table IV, online only. The use of ancillary
products at the initial implantation is described in Table V,
online only.
Renal assessment. At 12 months, no differences were
noted between the ZSR and SSR groups with respect to
SCr increase of 30%, creatinine-based renal insufficiency, or
renal failure requiring dialysis. In only one patient in each of
the pivotal study arms did renal function deteriorate to the
point that dialysis was initiated. Only 2.5% of patients in the
ZSR group and 3.4% of patients in the SSR group had SCr
2.0 mg/dL at 12 months. The cumulative incidence of
renal artery occlusion was 1.2% in the ZSR group and 1.7%
in the SSR group. Renal infarcts were noted in three
patients (1.8%) in the ZSR group and one patient (1.7%) in
the SSR group. Additional details are addressed in a sepa-
rate article.19
Rupture and conversion. There were no instances of
rupture in the ZSR group. A contained rupture, attributed
to the proximal migration of a distal iliac limb, required
conversion in a patient in the ZHR group at 222 days
l through 12 months in the standard-risk surgical group
isk, endovascular group (ZSR; red line) and high-risk,
truncated at 12 months, at which point there was no
9). B, Similar Kaplan-Meier plot of AAA-related survival
24 months for ZSR group (red line) and ZHR group
e ZSR group compared with the SSR group (P  .04).
s, all related to the procedure. Within 12 months, seven
edure (myocardial infarction 28 days post-implantation)
isease, myocardial infarction, respiratory failure in two
matoma).rviva
ard-r
was
 .9
ough
in th
onth
proc
ver d
al he
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surgical repair in which the proximal attachment system
was left in place and a bifurcated graft was sewn to the
amputated trunk of the main body. Estimated freedom
from rupture rate was 100% for all groups at 30 days, and at
12 months was 100% for the ZSR group and 98.9% for the
ZHR group. No additional ruptures occurred between 12
and 24 months. Patients in the ZSR group exhibited a high
estimated freedom from conversion rate (99%) at 12
months. Three conversions were performed during the first
12 months of follow-up, including the previously described
rupture. In an additional patient with persistent type I
endoleak elective conversion was performed 248 days post-
implantation. The development of a remote visceral seg-
Fig 3. Percent of patients with decrease in aneurysm si
black, SSR.
Fig 5. Incidence of endment aneurysm mandated conversion in a third patient,
112 days post-implantation. Two more conversions were
required between 12 and 24 months. Both were performed
at 543 days post-implantation, because of graft infection
attributed to the hematogenous spread of Staphylococcus
aureus.
Device assessment. Endoleaks were evaluated at 0 to
30 days and at 12 and 24 months. The respective overall
endoleak rates in the ZSR group were 17%, 7.4%, and 5.4%
(Fig 5). There were no type I or type III endoleaks at the
24-month follow-up evaluation. Secondary interventions
were more frequent in the ZSR group than in the SSR
group (11% vs 2.5%; P  .03) through 12 months. Most
interventions (6%) were performed to treat endoleak. Type
ater than 5 mm, compared with baseline. White, ZSR;
in standard-risk group.ze greoleak
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Palmaz stent, and multiple interventions in one patient),
type II leaks in five patients (coil embolization), and type
III leak, attributed to a modular joint problem, in one
patient (limb extension). In addition, five procedures were
performed to treat renal stenoses, three procedures were per-
formed to address iliac issues (two femorofemoral bypasses,
one iliac stent), and one femorotibial bypass was
performed.
At 12 months, migration greater than 5 mm was noted
in four patients in the ZSR group (2.5%) and two patients
in the ZHR group (2.8%). No patients underwent second-
ary interventions, no migration exceeded 10 mm, and no
patients developed an endoleak, aneurysmal growth, or any
adverse events as the result of migration. These patients
were followed up for 24 months, with no aneurysm-related
adverse events. Through 12 months, six patients (1.7%)
were noted to have separation of at least one barb on the
suprarenal stent (Fig 6). Although one patient also met the
criteria for migration (movement 5 mm), no interven-
tions were performed over the 24-month follow-up. One
partial detachment of the suprarenal stent was noted (Fig 7,
online only). This was treated with a proximal extension
with a redundant uncovered stent with barbs. No stent
fractures were noted with radiographic evaluation. Over
the 24-month follow-up, six explanted devices were ana-
lyzed for device integrity. A single barb separation and two
stent apex fractures were noted. The cause of the stent
fractures, whether they occurred before or during the ex-
plant procedure, is subject to speculation, given the ab-
sence of detectable fractures on earlier radiographs. Addi-
tional explant findings included an expected amount of
solder corrosion (equivalent to 50% at 10 years) and
absence of any evidence of graft wear, suture breaks, or
corrosion of stent wire, gold markers, or barb wires. Solder
loss is believed to be unrelated to barb separation.
Fig 6. Barb separation can be appreciated on abdomin
remainder of the proximal fixation system.DISCUSSION
The relatively high rate of acute complications after
open surgical aneurysm repair,9,10 moderate concern about
long-term sequelae,11,20 and the overall morbidity of pa-
tients with aneurysmal disease have led to aggressive inves-
tigation of less invasive treatments. The ultimate desire of
such endeavors is to abolish the risk for rupture, minimize
associated complications, and eliminate the treated aneu-
rysm as a cause of death without adversely affecting the
lifestyle or functional ability of the patient. That endovas-
cular repair has been perceived as nondurable21 and asso-
ciated with long-term failure7,22-25 stresses the importance
of surrogate end points that suggest the reversal of the
natural history of aneurysmal disease. This trial was de-
signed, in a manner similar to previous studies,7,8,14 in an
attempt to define the safety of the device through compar-
ison of overall morbidity between patients with similar
physiologic risks undergoing open or endovascular repair.
The establishment of effectiveness was to be accomplished
with a number of surrogate assessments that suggest the
security of the repair with respect to long-term protection
from rupture and aneurysm-related death.
The absence of a randomized study design creates a
potential for bias, which prompted a comprehensive analy-
sis of between-group differences. The ZSR and SSR groups
had minor differences with respect to preoperative medical
risk factors; however, a number of anatomic measures dif-
fered. To account for these inequalities, propensity score
analyses were used to determine the effect of specific factors
such as age, weight, hypertension, aneurysm size, and
proximal neck length. Furthermore, subgroup analyses
were conducted to assess specific situations such as the
requirement to place suprarenal clamps, in an effort to
minimize design bias. These differences did not appear to
have a significant effect on relative morbidity rates in the
surgical and endovascular groups.
diograph. Arrows denote the separated barb from theal ra
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who received treatment with an endovascular approach.
This was analyzed with absolute freedom from any morbid
event, as well as with a conglomerate score. This finding
does not differ from previous endovascular grafting re-
ports,7,8 and when coupled with equivalent ZSR and SSR
mortality at 12 months confirms the safety of the device.
Similarly, the clinical utility with respect to in-hospital
recovery was improved in the ZSR group in all circum-
stances. While the frequency of secondary interventions was
lower in the SSR group compared with the ZSR group,
most repeat interventions were minimally invasive after
endovascular repair; however, there was one death related
to a secondary procedure.
The effectiveness of aneurysm repair is more difficult to
determine when only intermediate-term data are available
for analysis. The surrogate success measures were uniformly
high in both arms of the study. With the realization that
effectiveness cannot properly be assessed with intermedi-
ate-term follow-up data, it is reassuring to observe that
significant sac shrinkage was noted in more than 66% of
patients at 12 months, and 75% of patients at 24 months
(Fig 3; Fig 4, online only, demonstrates continued reduc-
tion of sac size through the follow-up duration). The
observed aneurysm shrinkage, coupled with a low endoleak
rate, defines the effect of this device design on sac behavior.
It is important to note that in all cases in which aneurysm
growth was noted there were defined causes that prompted
therapeutic intervention. These facts support the concept
that the natural history of aneurysmal disease, mainly
growth and rupture, has been reversed with use of this
prosthesis.
The absence of any acute conversions, and the need for
only three conversions through the first 12 months of
follow-up and two subsequent conversions through 24
months demonstrate the low likelihood of deviation from
planned endovascular management of the aneurysm. A
careful retrospective review of the single case of aneurysm
rupture in the trial was conducted. Post-procedural films
depicted a limited sealing and fixation zone in the right iliac
artery. Proximal migration of the right limb into the aneu-
rysm sac was hypothesized to have caused acute repressur-
ization of the sac, leading to rupture. This has led to more
careful assessment of the distal fixation zone with respect to
patient selection, and greater attention to the position of
the iliac stent on follow-up imaging studies.
The use of barb-mediated fixation within the visceral
aortic segment is intended to provide secure proximal
fixation26 in a region of the aorta that is relatively free from
risk for dilatation.27-30 The effect of transrenal stenting
with an uncovered stent did not differ from the effect of
open surgery on the development of renal dysfunction.19
The greater proximal fixation force, relative to other
prostheses,25 afforded by the suprarenal stent with barbs
should help to provide a stable juxtarenal position. Al-
though six devices were observed to have a distal move-
ment greater than 5 mm, none migrated farther than the
10-mm distance required to meet current reporting stan-dards.15 During further follow-up through 24 months of
the six grafts that migrated, there were no aneurysm-
related adverse events or the necessity for any secondary
interventions. It is critical to understand that such a
definition and evaluation of Zenith migrations was based
on assessment of CT scans with a reconstruction thick-
ness of 3 mm or less. Use of scans with less longitudinal
resolution would cause errors in landmark identification
and localization of stent components. Although no clin-
ically significant migration was observed in this series, it
is likely that distal movement of the proximal fixation
system or proximal movement of the distal fixation sys-
tem to a point where the sealing zone is in jeopardy
should be treated with the use of additional components
or conversion to open repair, if possible. It must be
understood that short-term and intermediate-term anal-
ysis of device migration potential may underestimate the
true likelihood of such an event.22,25
Other potential sources of instability and late failure
relate to the durability of the stent graft. The three types
of structural failure that have been defined with this
prosthesis include barb separation, stent breakage, and
proximal stent separation. Barb separation was seen on
abdominal x-ray films in six patients and on examination
of the explanted stent graft in one patient. In five cases
only one barb (of 10 to 12 barbs) was affected, leaving 9
to 11 barbs intact, and in one case two barbs were
separated. Experience with an earlier versions (pre-
1996) of the Zenith prosthesis with only four barbs
demonstrated catastrophic migration and type I en-
doleak after separation of all barbs in a small number of
cases; hence the current design was created with signifi-
cant redundancy. In theory, multiple barbs help to pre-
vent separation by sharing the load, and they help to
maintain secure attachment even when one or more barbs fail.
No stent fractures were seen on any abdominal x-ray
films, yet the presence of two stent fractures among six
explants would suggest a higher prevalence. However, it is
not clear whether these fractures were present while the
stent graft was still in place or were caused by the trauma
of explantation. European and Australian experience
with earlier versions of the Zenith device showed some
fractures in the long stent proximal to the bifurcation.
The substitution of two short stents at this location in
1999 has added flexibility to that region and diminished
the risk for device integrity issues in the body of the graft.
More than 10,000 Zenith AAA Endovascular Graft de-
vices have been implanted worldwide, with relatively few
stent fractures noted, and no instances of fabric disrup-
tion have been reported. The single case of proximal
stent separation in the US study is worrisome. The same
phenomenon has been noted in five long-term implan-
tations outside of the United States. In these cases the
sutures that attached the uncovered suprarenal stent to
the graft material broke, which was followed by distal
migration of the covered component of the stent-graft
body. In response to these reports the manufacturer
doubled the number of sutures holding the proximal
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of the US trial. The effect of this design, implemented in
August 2002, was to increase the fatigue life of these
components by sevenfold, greatly reducing, if not abol-
ishing, the risk for proximal stent separation.
In addition to information on safety and effectiveness,
this study provided an indirect assessment of versatility.
No data were recorded for patients rejected from inclu-
sion in the endovascular arms of the study, but the
selection criteria, arterial anatomy in enrolled patients,
and sizes of stent grafts all suggest that the Zenith system
can be used in a large number of patients who may not be
candidates for any of the other approved devices. Al-
though sizing methods may differ among commercially
available devices, 41% of the main body components
were wider than 28 mm, and 34% of the iliac limb
components were 18 mm or wider. These sizing regi-
mens enable treatment of preoperative neck diameters as
large as 28 mm, and preservation of internal iliac arteries
in appropriate candidates with common iliac artery di-
ameters as large as 20 mm.
The decreased morbidity and equivalent mortality
demonstrate the safety of the Zenith endovascular grafting
system in comparison with surgical controls. The effective-
ness of the device in treating infrarenal AAAs is confirmed
by the extremely low incidence of aneurysm rupture or
aneurysm-related mortality, and clear evidence that the
natural history of aneurysmal disease is reversed in more
than 75% of patients, with documented sac size decrease.
Complete aneurysm exclusion was high, with a low inci-
dence of endoleak at 12 and 24 months. These benefits
were noted in the absence of clinically relevant migration,
detrimental effect on renal function from an uncovered
suprarenal stent (compared with open surgery), and signif-
icant durability issues. Furthermore, the ability to treat
proximal necks and iliac arteries with greater diameters, in
conjunction with suprarenal barb-mediated fixation, will
enable minimally invasive repair to be offered to a broader
population of subjects. Although uncommon, device integ-
rity issues demonstrate the importance of long-term radio-
graphic follow-up to assist with identification of unforeseen
failure modes, but more important, for identification of
potentially treatable scenarios before adverse clinical se-
quelae develop.
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